Palvella Therapeutics (PVLA) Common Equity (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Common Equity data on file, last reported at $232.3 million in Q1 2026.

• On a quarterly basis, Common Equity rose 318.0% year-over-year to $232.3 million in Q1 2026; TTM through Mar 2026 was $232.3 million, a 318.0% increase from a year earlier, with the FY2025 full-year figure at $28.0 million, down 55.3% from the prior year.
• Common Equity for Q1 2026 stood at $232.3 million, up from $28.0 million in the prior quarter.
• Over the last five years, Common Equity for PVLA reached as high as $232.3 million in Q1 2026 and fell as low as -$93.8 million in Q4 2022.
• Historically, Common Equity has averaged $13.9 million across 5 years, with a median of $30.5 million in 2023.
• Across the five-year window, Common Equity jumped 5722.52% in 2023 and slumped 597.3% in 2024, its largest moves.
• Year by year, Common Equity stood at -$93.8 million in 2022, then gained by 20.57% to -$74.5 million in 2023, then jumped by 184.06% to $62.6 million in 2024, then slumped by 55.3% to $28.0 million in 2025, then soared by 730.19% to $232.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $232.3 million in Q1 2026, $28.0 million in Q4 2025, and $38.7 million in Q3 2025.